Verona seeking NASDAQ listing

Pulmonary and inflammatory diseases company Verona Pharma plc (LSE:VRP) filed to raise up to $86.3 million in a listing of ADSs on NASDAQ underwritten by Jefferies, Stifel, Wedbush PacGrow and Suntrust.

Verona expects data in 4Q17 from an ongoing Phase IIa study of lead candidate RPL554 as an add-on therapy to treat chronic obstructive pulmonary disorder (COPD). A Phase IIb study is to begin in 2H18. Next half, the company plans to start a separate Phase IIb study of RPL554 as a single agent maintenance therapy for COPD, with data expected in 2H18...